CPC A01K 67/0278 (2013.01) [C07K 14/4703 (2013.01); C07K 14/705 (2013.01); C07K 14/70503 (2013.01); C07K 14/70596 (2013.01); C07K 16/2803 (2013.01); C12N 15/8509 (2013.01); G01N 33/5011 (2013.01); G01N 33/5014 (2013.01); G01N 33/5055 (2013.01); G01N 33/5088 (2013.01); A01K 2207/12 (2013.01); A01K 2207/15 (2013.01); A01K 2217/052 (2013.01); A01K 2217/072 (2013.01); A01K 2217/15 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0331 (2013.01); A01K 2267/0381 (2013.01); C07K 2319/00 (2013.01); C07K 2319/02 (2013.01); G01N 2333/70596 (2013.01)] | 12 Claims |
1. A genetically modified mouse whose genome comprises a replacement of a genomic fragment comprising exons 2-7 of a mouse CD47 gene at an endogenous mouse CD47 locus with a human genomic fragment comprising exons 2-7 of a human CD47 gene to form a humanized CD47 gene,
wherein the exons of the humanized CD47 gene consist of exon 1 of the mouse CD47 gene, exons 2-7 of the human CD47 gene, and the remaining exons downstream of exon 7 of the mouse CD47 gene,
wherein exons 2-7 of the human CD47 gene encode an amino acid sequence that is at least 98% identical with the amino acid sequence as set forth in amino acids 16-292 of SEQ ID NO: 10,
wherein the humanized CD47 gene is under control of the endogenous mouse CD47 promoter at the endogenous mouse CD47 locus, and
wherein the mouse expresses a humanized CD47 protein encoded by the humanized CD47 gene.
|